Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (+0.18%) is trading higher today, lagging the S&P 500 (+0.64%)<strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>The Medicines Co (<strong>MDCO</strong> +18.29%) positive Repatha data from Amgen last night</li><li>Axovant Sciences (<strong>AXON</strong> +8.7%) enters into a $55.0 million debt financing agreement; in connection, the co issued Hercules Capital (HTGC) a warrant to purchase up to 274,086 of its common shares at an exercise price of $12.04/share</li><li>ACADIA Pharma (<strong>ACAD</strong> +3.16%) vague speculation of interest from AstraZeneca (AZN)</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Neos Therapeutics (<strong>NEOS</strong> -13.79%) provides corporate update in conjunction with today's common stock offering; co sees Q4 revs just short of estimates</li><li>Pernix Therapeutics (<strong>PTX</strong> -17.11%) provides an update on the Company's arbitration with GlaxoSmithKline (GSK); the arbitration tribunal issued opinions in favor of GSK, awarding it damages and fees in the amount of approximately $35 million</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Cambrex (<strong>CBM</strong> +17.94%) beats by $0.19, beats on revs; issues 2017 guidance</li><li>Amgen (<strong>AMGN</strong> +3.65%) beats by $0.10, beats on revs; guides FY17 EPS in-line, revs below consensus</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>athenaHealth (<strong>ATHN</strong> -10.6%) beats by $0.11, misses on revs; guides FY17 revs in-line</li><li>PerkinElmer (<strong>PKI</strong> -3.83%) reports Q4 (Dec) results, guides FY17 excluding the Medical Imaging business being divested</li><li>Pacific Biosciences (<strong>PACB</strong> -3.49%) beats by $0.02, beats on revs; announces intention to offer and sell up to an aggregate offering price of $60 mln of shares of its common stock from time to time, through an 'at the market offering'</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Array Biopharma (<strong>ARRY</strong> -3.76%) downgraded to Neutral from Overweight at JP Morgan</li><li>Clovis Oncology (<strong>CLVS</strong> -4.01%) downgraded to Sell at Chardan Capital Markets; tgt $36</li><li>PARAXEL (<strong>PRXL</strong> -2.89%) downgraded to Sell from Hold at Deutsche Bank</li></ul>"